The Company ranked first in Asia among the residential real estate developers with a score of 100 out of 100 in the Development Benchmark. In the Standing Investments Benchmark, it ranked 8th in Asia in the category of Diversified – Office/ Retail with a score of 90 out of 100.

Lodha has also received the esteemed recognition of GRESB Global Sector Leader in Residential Development.

GRESB data is used by capital providers and asset managers to benchmark investments across portfolios and to better understand the opportunities, risks and choices that need to be made as the industry transitions to a more sustainable future.

The Assessment evaluates performance against the components of Management, Performance and Development which have indicators allocated to one of the three dimensions of ESG.

Sharing his views on this momentous achievement, Aun Abdullah, Head – ESG, Lodha said, “Sustainability is at the core of all that we do at Lodha. Our vision is to redefine urban development and lead India’s transition to achieve Net Zero by 2070. This recognition by GRESB is an assertion of our dedication to make a net positive impact on both society and environment.”

“GRESB Sector Leaders embody the industry’s champions, leading the charge towards a net-zero future and propelling the sector forward. We wholeheartedly commend this year’s Sector Leaders for their dedication, leadership and commitment to ESG principles and sustainability,” said Sebastien Roussotte, CEO, GRESB.

Also Read: Lodha (Macrotech) takes over property belonging to Neptune Developer

The post Lodha recognized as the ‘Global Sector Leader in Sustainability’ by GRESB appeared first on Square Feat India.

By Varun Singh

Lodha, closed a deal with Encube Ethicals, an integrated pharmaceutical company dedicated to topical products, to develop ~100,000 sq. ft. flagship R&D ‘Centre of Excellence’ at Palava. The project is part of the Lodha Lifesciences Hub, which is spread across 25 acres and is Mumbai’s first systematically developed life sciences cluster.

Expected to complete by 2023, the project will entail the development of Encube Ethicals’ R&D Centre of Excellence. In lines with Lodha’s commitment to fostering growth and contributing towards the larger goal of nation building, this strategic partnership will further provide a host of job opportunities in the city.

This project will be carried out in two phases, with the first phase being delivered by next year. Encube Ethicals plans to have 250 R&D-related jobs in the first building itself.

Despite the presence of majority of Indian life sciences companies’ headquarters in Mumbai, the desired R&D ecosystem has not been developed yet in MMR, given the lack of quality and compliant spaces, and infrastructure. The Lodha Lifesciences Hub at Palava offers next-generation lab spaces. It is built on the core principles of ESG with a host of ecosystem benefits, 100% compliant spaces, and all requisite government approvals in place. It is centrally located with close proximity to the current hubs of Mahape, Taloja, Ambernath, and more than ~1000 R&D employees are already residing in Palava.

Mehul Shah, MD, Encube Ethicals, said, “Lodha Lifesciences Hub at Palava provides a unique value proposition for life sciences R&D centres – high quality development, 100% compliance, streamlined approval process and talent friendly ecosystem. Encube’s partnership with Lodha for its flagship R&D Center of Excellence is expected to spread across ~100,000 sq. ft. Encube’s focus of 24+ years in topicals research will be leveraged to expand its domestic and global product portfolio.”

Shaishav Dharia, CEO, Townships, and Rental Assets, Lodha, said, “With this association, we are elated to achieve the milestone of building Mumbai’s first systematically developed life sciences cluster. Partnerships like these further leverage Lodha’s pledge towards the nation’s economic growth and the development of the country at large. Understanding the specific requirements to set up an advanced R&D hub in a space like MMR, Lodha Lifesciences Hub at Palava with its plethora of benefits serves as a one-stop solution and similar deals like the one with Encube Ethicals will further help fortify pharma-centric developments in the area.”

Along with residential and commercial hubs for the residents, Palava is also evolving into a greater location that now comprises pharma and R&D spaces. Additionally, Palava Industrial and Logistics Parks recently inked a deal with Aptar Pharma, a US based global manufacturer of consumer dispensing packaging and drug delivery devices.

The post Lodha launches its Lifesciences Hub at Palava with Encube Ethicals as their first client appeared first on Square Feat India.

By Varun Singh

Mumbai developers are known for making good money of their investments.

However, the pandemic had hit everyone pretty hard.

The reason being everything came to a standstill, people were interested in saving money for health instead of investing in property.

But with restrictions being eased by governments across the globe, the market is looking good.

A Mumbai based developer in the month of September made pre sales worth Rs 1100 crore in UK.

The developer in another project in London made sales worth Rs 350 crore in the last quarter.

Not keeping much of a secret, the developer is Lodha, which on Monday morning informed the stock exchange this major development.

The developer while providing an update on the performance of their UK investments claimed the mega sales.

In their 1 Grosvenor Square, London (GSQ) project, in the month of September, the project achieved Pre Sales of £110 million (Rs 1100 crores).

The reason for this bumper pre sales is, “Travel restrictions to the UK for visitors from the USA and Europe were eased starting in August 2021, allowing prospective purchasers to visit 1 Grosvenor Square development for the first time since its readiness.”

The statement by Lodha read, “The current performance exceeds our business plan and if the trend continues without any further unforeseen events, we expect to sell out the project ahead of our business plan of FY 24, expediting release of capital for our growth and deleveraging.”

Not only this Lodha managed to achieve a pre sales figure of Rs 350 crore in another London project.

The second project is Lincoln Square, London (LSQ), where the developer achieved Pre Sales of £35 million (Rs 350 crores) during the quarter,

This apparently is their best ever quarterly performance.

Lodha has several projects across the Mumbai Metropolitan Region. But as an Indian we always feel proud when an Indian firm does well even in foreign soil.

Also Read: Lodha clocks over Rs 550 crore sale in July 2020

The post Mumbai Developer Made Sales Worth ₹1100 Crore in UK in September appeared first on Square Feat India.